Provided by Tiger Trade Technology Pte. Ltd.

FOSUN PHARMA

17.820
-0.370-2.03%
Volume:3.66M
Turnover:66.35M
Market Cap:47.19B
PE:11.99
High:18.500
Open:18.270
Low:17.800
Close:18.190
52wk High:25.915
52wk Low:14.505
Shares:2.65B
HK Float Shares:530.00M
Volume Ratio:2.02
T/O Rate:0.69%
Dividend:0.46
Dividend Rate:2.56%
EPS(LYR):1.487
ROE:6.95%
ROA:1.40%
PB:0.83
PE(LYR):11.99
PS:0.95

Loading ...

Shanghai Fosun Pharma - Drug Registration Application for Sodium Nitroprusside Injection Approved by Nmpa

THOMSON REUTERS
·
Apr 30

Fosun Pharma Maintains Stable Share Base in April; 0% New Issuance, Public Float Compliant

Bulletin Express
·
Apr 30

FOSUN PHARMA Subsidiary Receives Regulatory Approval for Sodium Nitroprusside Injection

Stock News
·
Apr 30

Fosun Pharmaceutical Reports 14% Higher Profit in Q1

MT Newswires Live
·
Apr 29

Press Release: Fosun Pharma Announces Q1 2026 Results: Net Profit Attributable to Shareholders After Deducting Non-Recurring Gains and Losses Increased by 21.96% YoY, With Strong Pipeline Execution

Dow Jones
·
Apr 28

Morgan Stanley Raises Fosun Pharma's Revenue Forecast, Sets HK$32 Target with "Overweight" Rating

Stock News
·
Apr 22

FOSUN PHARMA’s 2025 ESG Report Highlights: AA MSCI Rating, RMB 5.91 Billion R&D Spend, and Strong Green, Social Commitments

Bulletin Express
·
Apr 21

Fosun Pharma Releases 2025 ESG and Sustainability Report

Bulletin Express
·
Apr 21

复星医药2025年报:净利润同比增至33.71亿元,业务与治理结构持续优化

Bulletin Express
·
Apr 21

FOSUN PHARMA Announces Release of 2025 Annual Report and Updates Shareholder Communication Arrangements

Bulletin Express
·
Apr 21

BRIEF-Shanghai Fosun Pharma Unit Received Approval From NMPA

Reuters
·
Apr 14

Fosun Pharma Unit Gets China Nod for Amyloidosis Drug Trial

MT Newswires Live
·
Apr 14

Fosun Pharma receives NMPA green light for Phase I/II trials of dual-target CAR-T therapy FKC289

Bulletin Express
·
Apr 14

Shanghai Fosun Pharma - Unit Received Approval From Nmpa for Phase I/Ii Clinical Trial of Fkc289 Injection

THOMSON REUTERS
·
Apr 14

FOSUN PHARMA Subsidiary Receives Approval for Phase I Trial of HLX05-N Cancer Treatment

Stock News
·
Apr 14

Hong Kong Market Announcement Highlights: VGT Launches IPO with CPE Rosewood and Janchor Fund as Cornerstone Investors

Stock News
·
Apr 13